Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Colon Cancer
Interventions
DRUG

Doublet or triplet chemotherapy combined with cetuximab

"chemotherapy+cetuximab combination therapy,chemotherapy regimens include FOLFOX, FOLFIRI, XELOX, or mFOLFOXIRI.~Cetuximab first dose 400 mg/m2, followed by cetuximab 250 mg/m2 every 2 weeks;~mFOLFOX6: oxaliplatin 85 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h) for up to 12 cycles;~XELOX (biweekly): oxaliplatin 85 mg/m2 (day 1), capecitabine 1000 mg/m2, bid, d1-10;~FOLFIRI: irinotecan 180 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h), Up to 12 cycles;~mFOLFOXIRI: oxaliplatin 85 mg/m2 (day 1), irinotecan 150 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1) and 5-FU 2400 mg/m2 CIV (46 h)."

Trial Locations (1)

250012

RECRUITING

Qilu hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER